AP646A - Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. - Google Patents

Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. Download PDF

Info

Publication number
AP646A
AP646A APAP/P/1997/001092A AP9701092A AP646A AP 646 A AP646 A AP 646A AP 9701092 A AP9701092 A AP 9701092A AP 646 A AP646 A AP 646A
Authority
AP
ARIPO
Prior art keywords
fumagillol
preparation
fumagillin
drugs
ester
Prior art date
Application number
APAP/P/1997/001092A
Other languages
English (en)
Other versions
AP9701092A0 (en
Inventor
Jean-Michel Molina
Francis Deriyubm
Original Assignee
Sanofi Synthelabo
Hopitaux Paris Assist Publique
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo, Hopitaux Paris Assist Publique filed Critical Sanofi Synthelabo
Publication of AP9701092A0 publication Critical patent/AP9701092A0/xx
Application granted granted Critical
Publication of AP646A publication Critical patent/AP646A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Epoxy Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
APAP/P/1997/001092A 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections. AP646A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9503549 1995-03-27
PCT/FR1996/000448 WO1996030010A2 (fr) 1995-03-27 1996-03-26 Utilisation du fumagillol et ses derives pour preparer les medicaments destines a combattre les infections intestinales

Publications (2)

Publication Number Publication Date
AP9701092A0 AP9701092A0 (en) 1997-10-31
AP646A true AP646A (en) 1998-04-27

Family

ID=9477436

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1997/001092A AP646A (en) 1995-03-27 1996-03-26 Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.

Country Status (25)

Country Link
US (1) US5900431A (OSRAM)
EP (1) EP0817626B1 (OSRAM)
JP (1) JP3260378B2 (OSRAM)
KR (1) KR100286920B1 (OSRAM)
CN (1) CN1072485C (OSRAM)
AP (1) AP646A (OSRAM)
AT (1) ATE172641T1 (OSRAM)
AU (1) AU706161B2 (OSRAM)
CA (1) CA2216623C (OSRAM)
CZ (1) CZ286821B6 (OSRAM)
DE (1) DE69600879T2 (OSRAM)
DK (1) DK0817626T3 (OSRAM)
EA (1) EA000150B1 (OSRAM)
ES (1) ES2128846T3 (OSRAM)
FR (1) FR06C0014I2 (OSRAM)
HU (1) HU224028B1 (OSRAM)
IS (1) IS2048B (OSRAM)
NO (1) NO315968B1 (OSRAM)
NZ (1) NZ304906A (OSRAM)
OA (1) OA10515A (OSRAM)
PL (1) PL183378B1 (OSRAM)
SK (1) SK283883B6 (OSRAM)
TR (1) TR199701048T1 (OSRAM)
UA (1) UA41446C2 (OSRAM)
WO (1) WO1996030010A2 (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL183378B1 (pl) * 1995-03-27 2002-06-28 Assist Publ Hopitaux De Paris Zastosowanie fumagilolu i jego pochodnych do wytwarzania jelitowych środków przeciwinfekcyjnych
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
ES2286998T3 (es) 1999-02-26 2007-12-16 Sanofi-Aventis Formulacion estable que contiene fumagillina.
JP3265394B1 (ja) * 2001-03-14 2002-03-11 泰三 矢野 アクリル系樹脂手袋
DE10341887A1 (de) * 2003-09-09 2005-03-31 Leopold Kostal Gmbh & Co. Kg Elektrisches Schaltermodul
FR2886855B1 (fr) * 2005-06-08 2009-07-17 Agronomique Inst Nat Rech Utilisation de la fumagilline et de ses derives pour augmenter la biodisponibilite des lactones macrocyliques
JP5557746B2 (ja) * 2007-11-28 2014-07-23 メルサナ セラピューティックス，インク． 生体適合性生分解性フマギリンアナログ複合体
AU2009270799B2 (en) * 2008-07-18 2016-05-19 Zafgen, Inc. Methods of treating an overweight or obese subject
WO2010065883A2 (en) 2008-12-04 2010-06-10 Zafgen Corporation Method of treating an overweight or obese subject
US20120004162A1 (en) 2008-12-04 2012-01-05 Vath James E Methods of Treating an Overweight or Obese Subject
WO2013055385A2 (en) 2011-10-03 2013-04-18 Zafgen Corporation Methods of treating age related disorders
AU2010303270A1 (en) 2009-10-09 2012-05-03 Zafgen Corporation Sulphone compounds for use in the treatment of obesity
EP2521719B1 (en) 2010-01-08 2015-07-29 Zafgen, Inc. Fumagillol type compounds and methods of making and using same
WO2011085198A1 (en) 2010-01-08 2011-07-14 Zafgen Corporation Metap-2 inhibitor for use in treating benign prostatic hypertrophy (bph)
WO2011127304A2 (en) 2010-04-07 2011-10-13 Zafgen Corporation Methods of treating an overweight subject
KR20130043207A (ko) 2010-07-22 2013-04-29 자프겐 인크. 트리시클릭 화합물 및 이의 제조 및 사용 방법
PH12013500934A1 (en) 2010-11-09 2022-10-24 Zafgen Inc Crystalline solids of a metap-2 inhibitor and methods of making and using same
US9173865B2 (en) 2010-11-29 2015-11-03 Zafgen, Inc. Treatment of obesity using non-daily administration of 6-O-(4-dimethylaminoethoxy) cinnamoyl fumagillol
WO2012103333A1 (en) 2011-01-26 2012-08-02 Zafgen Corporation Tetrazole compounds and methods of making and using same
CA2829204C (en) 2011-03-08 2019-12-24 Zafgen, Inc. Oxaspiro[2.5]octane derivatives and analogs
PH12013502261A1 (en) 2011-05-06 2022-10-26 Zafgen Inc Partially saturated tricyclic compounds and methods of making and using same
KR20140053013A (ko) 2011-05-06 2014-05-07 자프겐 인크. 삼환식 설폰아마이드 화합물 그리고 그의 제조방법 및 그를 이용하는 방법
AU2012253760B2 (en) 2011-05-06 2016-02-04 Zafgen, Inc. Tricyclic pyrazole sulfonamide compounds and methods of making and using same
WO2013109739A1 (en) 2012-01-18 2013-07-25 Zafgen, Inc. Tricyclic sulfonamide compounds and methods of making and using same
BR112014017780A8 (pt) 2012-01-18 2017-07-11 Zafgen Inc Compostos de sulfona tricíclicos e métodos para fazer e usar os mesmos
US9260419B2 (en) 2012-05-07 2016-02-16 Zafgen, Inc. Polymorphic salt of a metap-2 inhibitor and methods of making and using same
US9839622B2 (en) 2012-05-08 2017-12-12 Zafgen, Inc. Methods of treating hypothalamic obesity
JP6177888B2 (ja) 2012-05-09 2017-08-09 ザフゲン，インコーポレイテッド フマギロール型化合物ならびにその製造および使用方法
JP6169716B2 (ja) 2012-11-05 2017-07-26 ザフゲン，インコーポレイテッド 肝疾患を治療する方法
CN104870433A (zh) 2012-11-05 2015-08-26 扎夫根股份有限公司 三环化合物及其制备方法和用途
US9868717B2 (en) 2012-11-05 2018-01-16 Zafgen, Inc. Tricyclic sulphonamide compounds and methods of making and using same
AU2014236528A1 (en) 2013-03-14 2015-09-24 Zafgen, Inc. Methods of treating renal disease and other disorders
AR105671A1 (es) 2015-08-11 2017-10-25 Zafgen Inc Compuestos heterocíclicos de fumagillol y sus métodos de elaboración y uso
CN106432255A (zh) 2015-08-11 2017-02-22 扎夫根公司 烟曲霉素醇螺环化合物和制备和使用其的方法
CN106591389B (zh) * 2015-10-15 2019-10-11 中国科学院微生物研究所 一种利用烟曲霉菌生产烟曲霉素的方法
CN105622593B (zh) * 2016-02-25 2018-06-26 中国农业科学院蜜蜂研究所 一种烟曲霉素的提取方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019946A1 (en) * 1993-03-01 1994-09-15 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2791530A (en) * 1953-08-31 1957-05-07 Abbott Lab Stabilized fumagillin compositions
JPH0629278B2 (ja) * 1985-06-26 1994-04-20 藤沢薬品工業株式会社 オキサスピロオクタン化合物
US5135920A (en) * 1988-11-16 1992-08-04 Takeda Chemical Industries, Ltd. Angiostatic agents
EP0541716A1 (en) * 1990-07-27 1993-05-19 Repligen Corporation Novel methods and compositions for treatment of angiogenic diseases
PL183378B1 (pl) * 1995-03-27 2002-06-28 Assist Publ Hopitaux De Paris Zastosowanie fumagilolu i jego pochodnych do wytwarzania jelitowych środków przeciwinfekcyjnych
EP0799616A1 (en) * 1996-04-01 1997-10-08 Takeda Chemical Industries, Ltd. Oral composition comprising a fumagillol derivative
CA2210600A1 (en) * 1996-07-17 1998-01-17 Takashi Houkan Inhibitor of tumor metastasis or recurrence
WO1998005293A2 (en) * 1996-08-02 1998-02-12 The Children's Medical Center Corporation Method of regulating the female reproductive system through angiogenesis inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994019946A1 (en) * 1993-03-01 1994-09-15 Emory University Treatment of microsporidial and acanthamoeba keratoconjunctivitis with topical fumagillin

Also Published As

Publication number Publication date
US5900431A (en) 1999-05-04
DE69600879T2 (de) 1999-06-02
WO1996030010A3 (fr) 1996-11-28
SK130797A3 (en) 1998-03-04
SK283883B6 (sk) 2004-04-06
EP0817626B1 (fr) 1998-10-28
NZ304906A (en) 1999-06-29
FR06C0014I2 (OSRAM) 2006-12-29
IS4557A (is) 1997-09-11
TR199701048T1 (xx) 1998-01-21
PL322470A1 (en) 1998-02-02
NO974466D0 (no) 1997-09-26
MX9707150A (es) 1998-07-31
NO974466L (no) 1997-09-26
FR06C0014I1 (OSRAM) 2006-11-17
ES2128846T3 (es) 1999-05-16
CZ304997A3 (en) 1997-12-17
AU5278696A (en) 1996-10-16
CN1179715A (zh) 1998-04-22
JPH11506421A (ja) 1999-06-08
AP9701092A0 (en) 1997-10-31
HUP9801220A2 (hu) 1999-09-28
KR19980703271A (ko) 1998-10-15
CN1072485C (zh) 2001-10-10
EP0817626A2 (fr) 1998-01-14
EA199700267A1 (ru) 1998-04-30
HUP9801220A3 (en) 2001-10-29
DE69600879D1 (de) 1998-12-03
PL183378B1 (pl) 2002-06-28
WO1996030010A2 (fr) 1996-10-03
CA2216623C (en) 2005-05-31
HU224028B1 (hu) 2005-05-30
NO315968B1 (no) 2003-11-24
KR100286920B1 (ko) 2001-04-16
CZ286821B6 (en) 2000-07-12
AU706161B2 (en) 1999-06-10
OA10515A (fr) 2002-04-24
IS2048B (is) 2005-09-15
EA000150B1 (ru) 1998-10-29
DK0817626T3 (da) 1999-07-12
ATE172641T1 (de) 1998-11-15
CA2216623A1 (en) 1996-10-03
JP3260378B2 (ja) 2002-02-25
UA41446C2 (uk) 2001-09-17

Similar Documents

Publication Publication Date Title
AP646A (en) Use of fumagillol and derivatives thereof for preparing medicaments against intestinal infections.
JPH0621079B2 (ja) 下痢止め組成物及びその用途
AU608853B2 (en) Inhibitors of glycoprotein processing having anti- retroviral activity
EP0190851B1 (en) Improved antiinflammatory composition
JPH0610141B2 (ja) エイズウイルス性疾患処置剤
US4895851A (en) Use of oxoquinazoline derivatives in the treatment of hyperuricaemia
MXPA97007150A (en) Use of fumagilol and its derivatives to prepare medicines intended to combat intestine infections
US6593329B1 (en) Method for the treatment or prevention of coronary graft vasospasm
KR20010072640A (ko) 폐고혈압 치료방법
EP0555302A1 (en) Method of treating demyelinating disease
US7485642B2 (en) Method for treating septic shock
EP0402477B1 (en) Use of isocarbacyclins for preventing or treating organ diseases
Stratigos et al. Treatment of gonorrhoea with spectinomycin hydrochloride
JPH0132804B2 (OSRAM)
JPH04266822A (ja) システノール酸又はその胆汁酸抱合体を含有する血中コレステロール低下剤
US20070093519A1 (en) Anti-emetic uses of cannabinoid analogs
US20040044016A1 (en) Antiviral agents
JPS58210010A (ja) 抗腫瘍剤
JPH02174721A (ja) 脂質低下剤
JPH0899883A (ja) 膵炎治療剤